title: [Targeted treatment of chronic lymphocytic leukaemia].
abstract: The development of targeted treatment of chronic lymphocytic leukaemia (CLL) is changing the prognostic outlook for CLL patients. The B-cell antigen receptor pathway is identified as pivotal for CLL pathogenesis and CLL cell proliferation. Inhibition of this pathway by ibrutinib (Bruton's tyrosin kinase inhibition) and idelalisib (phosphatidylinositol 3-kinase inhibition) has recently shown impressive clinical results, also for CLL patients with relapsed/refractory disease and unfavourable prognostic markers. Apoptosis induction by inhibition of BCL2 with ABT-199 is reported with likewise promising clinical results.
authors.affiliation: Laboratory of Adrian Wiestner Lymphoid Malignancies Section, Hematology Branch, NHLBI, NIH Bld 10, CRC 3E-5140,10 Center Drive, 20892-1202 Bethesda, MD, USA. niemann@dadlnet.dk.
authors.forename: Carsten Utoft
authors.initials: CU
authors.lastname: Niemann
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000631:Aminopyridines; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D009025:Morpholines; D010078:Oxazines / Q000627:therapeutic use; D010880:Piperidines; D011687:Purines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D011947:Receptors, Antigen, B-Cell / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000631:Aminopyridines; D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D009025:Morpholines; D010078:Oxazines; D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011725:Pyridines; D011743:Pyrimidines; D052999:Quinazolinones; D011947:Receptors, Antigen, B-Cell; D013449:Sulfonamides; C551803:ibrutinib; D000225:Adenine; C579720:venetoclax; C523665:fostamatinib; C552946:idelalisib